



Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES PILOT PROJECT CONCLUSION

London, Ontario (August 17, 2009): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that COTI has received notification from Merck KGaA (FWB: MRK) of Darmstadt, Germany that it decided to discontinue the pursuit of compounds under the pilot project announced on October 17, 2007. The project called for COTI to identify drug discovery candidates for a specific oncology cellular target of importance to Merck KGaA.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS[®], which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis, colorectal cancer and alzheimer's disease.

For further information, please visit the website at www.criticaloutcome.com or contact 519-858-5157:

Michael Barr, Director of Business Development and Marketing; mbarr@criticaloutcome.com

Michael Cloutier, Chief Executive Officer: mcloutier@criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.